Literature DB >> 16245318

Akt activation correlates with adverse outcome in tongue cancer.

Erminia Massarelli1, Diane D Liu, J Jack Lee, Adel K El-Naggar, Lorenzo Lo Muzio, Stefania Staibano, Sabino De Placido, Jeffrey N Myers, Vassiliki A Papadimitrakopoulou.   

Abstract

BACKGROUND: Recent data have shown a significant association between phosphorylated-Akt (p-Akt) and failure of local disease control by radiation therapy in head and neck squamous carcinoma (HNSCC), and also that Akt activation correlates with histologic progression of HNSCC from premalignant lesions to invasive cancer. This study evaluated the role of Akt in previously untreated preneoplastic lesions of oral cavity and invasive tongue carcinoma on patient outcome and cancer development.
METHODS: PKB/Akt activation was assessed by immunohistochemistry using a phosphorylation state-specific antibody (Ser 473) in tongue cancer and preneoplastic specimens of oral cavity.
RESULTS: The expression of p-Akt was detected in 24 (46%) of the 52 available tongue cancer cases and in 10 (45%) of the 22 available preneoplastic lesions. In tongue cancer, with a median follow-up of 7.3 years, p-Akt was highly expressed in the cases that relapsed (15 of 17, 88%) or died of cancer (10 of 12, 83%). Disease-free survival was significantly shorter in cases with Akt expression (log rank test, P < 0.0001) independently of the stage and nodal status.
CONCLUSIONS: Expression of p-Akt correlated with worse outcome in patients with tongue cancer. This finding highlights the potential role of Akt as a prognostic marker and as a potential target for molecular therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16245318     DOI: 10.1002/cncr.21476

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

Review 1.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

2.  Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.

Authors:  Liwei Bao; Michael A Gorin; Manchao Zhang; Alejandra C Ventura; William C Pomerantz; Sofia D Merajver; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

4.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

5.  Integrin-linked kinase cytoplasmic and nuclear expression in laryngeal carcinomas.

Authors:  Anastasios K Goulioumis; Vasiliki Bravou; John Varakis; Panos Goumas; Helen Papadaki
Journal:  Virchows Arch       Date:  2008-09-24       Impact factor: 4.064

6.  Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.

Authors:  Argun Akcakanat; Aysegul Sahin; Alexandra N Shaye; Marco A Velasco; Funda Meric-Bernstam
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

7.  A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.

Authors:  Panomwat Amornphimoltham; Vyomesh Patel; Kantima Leelahavanichkul; Robert T Abraham; J Silvio Gutkind
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

8.  YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets.

Authors:  R Ehsanian; M Brown; H Lu; X P Yang; A Pattatheyil; B Yan; P Duggal; R Chuang; J Doondeea; S Feller; M Sudol; Z Chen; C Van Waes
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

9.  Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias.

Authors:  Ivy F L Tsui; Catherine F Poh; Cathie Garnis; Miriam P Rosin; Lewei Zhang; Wan L Lam
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

10.  Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.

Authors:  Jin-E Yao; Min Yan; Zhong Guan; Chao-Bin Pan; Liang-Ping Xia; Chuan-Xing Li; Li-Hui Wang; Zi-Jie Long; Yan Zhao; Ming-Wei Li; Fei-Meng Zheng; Jie Xu; Dong-Jun Lin; Quentin Liu
Journal:  Mol Cancer       Date:  2009-11-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.